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Background
Anemia is common problem in patients with chronic kidney disease (CKD) 
and contributes to increased risk of poor clinical outcomes. In treating 
anemia in CKD patients, erythropoiesis stimulating agents (ESA) resistance 
is an important issue and hepcidin is suggested as a key peptide of ESA 
resistance. However, the clinical characteristics of hepcidin and its role on 
ESA resistance have not been validated in large-scaled multicenter cohort. 
Moreover, the relative contribution of hepcidin and iron indices on anemia 
severity in CKD has been studied little. Therefore investigator designed and 
performed this study to confirm the known association between hepcidin, 
kidney function, ESA resistance, and anemia, and to identify the effect of 
hepcidin on clinical outcomes in non-dialysis CKD patients.
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Methods
Investigator reviewed data of 2238 patients from a large-scale multicenter 
prospective Korean study (2011–2016). Among 2238 patients whose mean 
age was 54.2 years, serum of 2113 patients were analyzed to measure 
serum hepcidin levels using competitive enzyme-linked immunosorbent assay. 
Iron indices were transferrin saturation (TSAT) and ferritin. Anemia was 
defined as hemoglobin (Hb) <13.0 g/dl in men and <12.0 g/dl in women. 
Mild, moderated, and severe anemia were defined as Hb <13.0 g/dl, <11.5 
g/dl, and <10.0 g/dl, respectively. The studied clinical outcomes were renal 
events, defined as a >50% decrease in kidney function from the baseline 
values, doubling of serum creatinine, or dialysis initiation, which were 
detected and adjudicated annually.
Results
Markers of inflammation and iron status were positively associated with 
serum hepcidin levels, regardless of CKD stage. However, estimated 
glomerular filtration rate was inversely associated with serum hepcidin levels 
(beta -0.007, P < 0.001), particularly in patients with CKD stages 3b–5, but 
not in those with CKD stages 1–3a. Iron supplementation was associated 
with increased serum hepcidin levels (beta 0.306, P = 0.001), particularly in 
patients with CKD stages 1–3a, but not in those with CKD stages 3b–5. 
Use of ESA was associated with increased serum hepcidin levels (beta 
0.802, P <0.001), particularly in patients with CKD stages 3b–5, but not in 
those with CKD stages 1–3a, and ESA dosage positively correlated with 
serum hepcidin levels. In subgroup analysis according to the causes of 
CKD, kidney function was negatively associated with serum hepcidin levels 
in patients with hypertensive nephropathy and glomerulonephritis. The 
positive association between ESA use and serum hepcidin levels was not 
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affected by causes of CKD. TSAT and serum hepcidin were significantly 
associated with anemia status, whereas serum ferritin was not, regardless of 
anemia severity. In patients with CKD1-3a, a 10% increase of TSAT was 
associated with severe anemia [odds ratio (OR) 0.628, 95% confidence 
interval (CI) 0.515-0.765; P <0.001] and moderate anemia (OR 0.672, 95% 
CI 0.476-0.950; P = 0.024), whereas a 10-ng/ml increase of serum hepcidin 
was associated with mild anemia (OR 1.360, 95% CI 1.115-1.659; P=0.002) 
and moderate anemia (OR 1.379, 95% CI 1.173-1.620; P <0.001) in patients 
with CKD 3b-5 on multivariate logistic analysis.  During a mean of 2.4 
years, 333 patients developed renal events (17.4%); 165 (8.6%) patients with 
functional deterioration and 275 (14.4%) patients with dialysis initiation. In 
penalized smoothing splines curve analysis, the hazard of renal events 
steadily increased with the increase of serum hepcidin levels. In multivariate 
Cox-proportional hazard regression analysis, the hazard ratio and its 95% CI 
in the third and the forth serum hepcidin quartile were 1.514 (1.025-2.237, 
P = 0.037) and 1.752 (1.183-2.596, P = 0.005), respectively, compared to 
the first serum hepcidin quartile. In subgroup analysis, increased serum 
hepcidin levels were associated with increased hazard of future renal events 
development, particularly in diabetic male patients with lower levels of Hb, 
TSAT, ferritin, inflammation, and kidney function.   
Conclusions
Investigator observed that kidney function was an independent factor of 
serum hepcidin levels. Increased serum hepcidin levels with the increase of 
ESA dosage may suggest the key role of hepcidin in ESA resistance. 
Although ferritin was not associated with anemia in CKD patients, regardless 
of kidney function, TSAT was associated with less severe anemia in early 
CKD patients, whereas serum hepcidin was associated with more severe 
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anemia in advanced CKD patients. In this study, increased serum hepcidin 
levels independently predict the progression of CKD in non-dialysis CKD 
patients. Diabetic male patients with lower levels of Hb, TSAT, ferritin, 
inflammation, and kidney function may need to be treated more meticulously 
with special attention to the development of CKD progression.
………………………………………
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Anemia is more prevalent in chronic kidney disease (CKD) patients than 
in general population, and the severity of anemia is increased with the 
progression of CKD [1,2]. Since anemia contributes to an increased risk for 
end stage renal disease, cardiovascular events, and death in CKD patients 
[3,4], identification of anemia-associated factors in CKD patients is of 
utmost importance. Erythropoietin is a peptide which is produced by renal 
interstitial fibroblasts and stimulates red blood cells (RBC) production in 
bone marrow [5]. As CKD progresses, the production of erythropoietin in 
kidney is diminished, causing normocytic, normochromic, and 
hypo-proliferative anemia [5]. Based on these features in CKD patients, there 
have been several attempts to treat anemia by replacing erythropoietin [6-9], 
but ultimately failed to improve clinical outcomes [6,7]. Secondary analyses 
have revealed that resistance to erythropoiesis stimulating agents (ESA) 
played an important role on the poor outcomes [10,11].
Since Tomas Ganz and the colleges found a new cysteine-rich human 
peptide and named  hepcidin after its origin in the liver (hep-) and 
antimicrobial properties (-cidin) in 2001 [12], many studies have found that 
it plays a key role on iron metabolism [13]. The biological receptor of 
hepcidin is ferroportin, an iron exporting transcellular channel located in 
cells that are sources of iron, including enterocytes, macrophages, and 
hepatocytes [14]. Binding of hepcidin to the ferroportin induces the 
internalization and degradation of ferroportin and disturbs iron efflux from 
cells to plasma, ultimately reducing serum iron levels and sequestering iron 
in iron storage sites [14]. This is why hepcidin is thought to be a 
fundamental peptide related to ESA resistance [15]. 
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The primary site of hepcidin synthesis is hepatocytes. The biological 
stimuli of hepcidin production is iron overload and inflammation, and the 
hepcidin production is suppressed by anemia and erythropoietic activity [16]. 
Because hepcidin is very small peptide (2.7 kDa), it is easily cleared by 
kidney, and the decreased kidney function may cause accumulation of the 
peptide [17,18]. Nonetheless, the association between serum hepcidin and 
kidney function have been suggested only in small single-center studies and 
the results were not consistent [17-27]. Moreover, unlike hypothetical key 
role of hepcidin in ESA resistance, previous studies have failed to provide 
hepcidin-related ESA resistance in real world [17,28]. Therefore, the 
uncertainties in clinical characteristics of hepcidin and its role on ESA 
resistance are needed to be evaluated further. 
Beyond the uncertainty of hepcidin and ESA resistance, the relative effect 
of conventional iron indices and hepcidin on anemia in CKD patients has 
also not been fully evaluated. Conventionally, transferrin saturation (TSAT) 
and serum ferritin have been used as serum iron indices [29,30]. TSAT and 
serum ferritin are markers of available serum iron and whole body iron 
storage, respectively [16,31]. Currently, guidelines for anemia in CKD 
patients have recommended iron replacement according to serum levels of 
TSAT and ferritin [9,32]. However, the effectiveness of these two iron 
indices with anemia in CKD is doubtful [33-36]. Unlike conventional iron 
indices, however, hepcidin has been significantly associated with anemia in 
CKD patients [18,19,22,27,37-39]. Therefore, comprehensive analysis of the 
relative contribution of conventional iron indices and hepcidin on anemia in 
CKD patients is warranted.
To dates, only few studies have explored the association between serum 
hepcidin level and adverse clinical outcomes. Niihata et al. reported that 
serum hepcidin levels predicted future anemia development in 335 
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non-dialysis CKD patients [37]. Wagner et al. analyzed 249 diabetic patients 
with CKD who were ESA-naïve, and reported that serum hepcidin levels 
were independently associated with CKD progression and mortality [40]. 
However, these previous studies relied on small population samples.
Therefore, investigator planned to perform the present study to confirm 
known association between hepcidin, kidney function, ESA resistance, and 
anemia, and to identify the effect of hepcidin on renal events in non-dialysis 
CKD patients using a large number of adults enrolled in the KoreaN cohort 
study for Outcome in patients With Chronic Kidney Disease (KNOW-CKD).
Material and methods
Participants
  The KNOW-CKD is a multicenter prospective cohort study in Korea of 
2238 patients with non-dialysis CKD stages 1–5 enrolled from February 
2011 through January 2016. The detailed design and methods of the 
KNOW-CKD were previously published (NCT01630486 at 
http://www.clinicaltrials.gov) [41]. The protocol of the KNOW-CKD adhered 
to the principles of the Declaration of Helsinki and was approved by the 
Institutional Review Board at each participating hospital including Seoul 
National University Hospital, Yonsei University Severance Hospital, Kangbuk 
Samsung Medical Center, Seoul St. Mary’s Hospital, Gil Hospital, Eulji 
Medical Center, Chonnam National University Hospital, and Pusan Paik 
Hospital. Written informed consent was obtained from all subjects. Estimated 
glomerular filtration rate (eGFR) was calculated by the equation of 
Modification of Diet in Renal Disease study formula [42]. CKD and its 
stages were defined using the Kidney Disease Improving Global Outcomes 
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2012 guidelines [43]. 
Serum hepcidin measurement
Serum hepcidin levels were measured at a central laboratory by 
competitive enzyme-linked immunosorbent assay (cELISA) using EIA5258 kit 
(DRG Diagnostics, Marburg, Germany), according to the manufacturer`s 
instructions. The intra- and inter-assay coefficients of variation ranged from 
2.1–9.9% and from 11.5–14.6%, respectively. The detectable maximum level 
was 80 ng/ml, with higher levels recorded as 80 ng/ml.  
Definitions 
Clinical data, including detailed demographic information and baseline 
laboratory results, were extracted from the electronic data management 
system (PhactaX). Hypertension was defined as physician diagnosis; systolic 
blood pressure (BP) ≥ 140 mm Hg or diastolic BP ≥ 90 mmHg or 
treatment with anti-hypertensive drugs. Diabetes was defined as physician 
diagnosis; fasting glucose ≥ 126 mg/dl, or treatment with insulin or oral 
anti-diabetic drugs. High income was defined as monthly household income 
more than 4.5 million won (approximately 4000 US dollars). Ever smoking 
was defined as past or current smoking. Body mass index was calculated as 
weight (kg) per square of height (m2). Anemia was defined as hemoglobin 
(Hb) <13.0 g/dl in men and <12.0 g/dl in women [32]. The severity of 
anemia were defined by the necessity of ESA: mild (Hb <13.0 g/dl, a level 
for which ESA should not be used to increase Hb levels intentionally), 
moderate (Hb <11.5 g/dl, a level for which ESA should be used to 
maintain Hb levels), and severe (Hb <10.0 g/dl, a level for which ESA 
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should be started), following KDIGO 2012 anemia guidelines [32]. TSAT 
(%) was calculated as serum iron × 100/ total iron binding capacity (TIBC). 
Dose of ESA was measured as weight-normalized epoetin-equivalent 
(IU/kg/week), with 1 µg of darbepoetin alfa converted to 331 units of 
epoetin [44]. Continuous erythropoietin receptor activator doses of 50 
µg/month, 75 µg/month, 100 µg/month, and 150 µg/month were converted 
to epoetin equivalents of 3000 IU/week, 4000 IU/week, 6000 IU/week, and 
8000 IU/week, respectively [2]. Patients were also sub-grouped by CKD 
stages into those with early (stage 1–3a) and advanced (stage 3b–5) CKD. 
The fourth quartile was defined as high serum hepcidin. Renal events are 
defined by a >50% decrease in eGFR from the baseline values, doubling of 
serum creatinine, or dialysis initiation, and detected and adjudicated annually 
[41].
Statistical analysis
The distributions of continuous variables were evaluated using histograms 
and Q-Q plots. Four variables, hepcidin, ferritin, high-sensitivity C-reactive 
protein (hsCRP), and urine protein-to-creatinine ratio (UPCR) were not 
normally distributed. Normally distributed continuous variables are expressed 
as mean ± standard deviation, non-normally distributed continuous variables 
as median (interquartile range), and categorical variables as percentages. 
P-trend was analyzed for normally distributed continuous variables by a 
linear-term of one-way analysis of variance (ANOVA), for non-normally 
distributed continuous variables by Jonckheere-Terpstra tests, and for 
categorical variables by a linear-by-linear association. Differences were 
analyzed by Bonferroni post-hoc analysis of one-way ANOVA for normally 
distributed continuous variables, Mann-Whitney U tests for non-normally 
distributed continuous variables, and chi-square tests for categorical variables. 
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The square roots of serum hepcidin levels and the logarithm of hsCRP, 
UPCR and ferritin were utilized in linear regression analysis. Odds ratio 
(OR) and 95% confidence interval (CI) were calculated by logistic regression 
analysis. A P value of < 0.05 was considered statistically significant. In 
multivariate analysis, variables with statistical significance on univariate 
analyses were chosen as covariates using enter method. For the estimated 
renal survival, the Kaplan-Meier method was employed, and the statistical 
significance was calculated using the log-rank test. Hazard ratio (HR) and 
its 95% confidence interval (CI) of serum hepcidin and its tertile group for 
renal events were assessed using Cox proportional hazard regression analysis. 
The assumption of proportional hazard was tested by log minus log plot for 
categorical variables and interaction analysis with time covariate using 
time-dependent Cox regression analysis for continuous variables. In 
multivariate Cox proportional hazard regression analysis, age, sex, serum 
ferritin, hsCRP, and variables with P <0.05 in univariate analysis were 
chosen as covariates. The relationship between serum hepcidin and renal 
events was plotted using the penalized smoothing spline method, using the 
“pspline” package in R Statistics (version 3.03). All analyses, unless 
otherwise specified, were performed using SPSS Version 22 (IBM Corp., 
Armonk, NY). 
Results
1. Clinical characteristics of serum hepcidin and its role on 
ESA resistance 
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Of the 2238 cohort subjects, 148 were excluded, including 126 with 
missing serum hepcidin levels and 23 with missing Hb levels. This analysis 
therefore included 2090 patients. The mean age of the 2090 study patients 
was 53.6 years and 61.1% were men. Mean eGFR was 50.3 ml/min/1.73m2 
and the proportions of patients with CKD stages 1, 2, 3a, 3b, 4 and 5 were 
11.9%, 18.3%, 18.0%, 21.7%, 23.5% and 6.6%, respectively. The causes of 
CKD were diabetic nephropathy (DMN) in 25.3% of patients, 
glomerulonephritis (GN) in 31.2%, hypertensive nephropathy (HN) in 20.1% 
and others (mostly autosomal dominant polycystic kidney disease, ADPKD) 
in 23.4%. ESA and iron supplements were administered to 7.6% and 14.7% 
of these patients, respectively.
Patients were divided into quartiles, with the first, second, third, and 
fourth quartiles defined as <6.6 ng/ml, 6.6–13.4 ng/ml, 13.4–25.1 ng/ml and 
≥25.1 ng/ml, respectively. Exploration of baseline characteristics in patients 
assorted by serum hepcidin quartile (Table 1.1) showed that increased serum 
hepcidin quartile was associated with increased age and an increased 
percentage of men, as well as with high rates of hypertension and diabetes. 
Moreover, increased serum hepcidin quartile was associated with a 
significant reduction in eGFR and significant increases in white blood cells 
(WBC) counts and hsCRP. Higher serum hepcidin quartile was also 
associated with higher rates of anemia, treatment with ESA and 
supplemental iron, and higher serum levels of TSAT and ferritin. 
Analysis of Hb levels and markers of iron metabolism and inflammation 
as a function of CKD stage (Table 1.2) showed that serum hepcidin levels 
increased with the progression of CKD stages. The median hepcidin levels 
in patients with CKD stages 1, 2, 3a, 3b, 4 and 5 were 7.7, 11.5, 11.6, 
12.5, 20.5 and 31.6 ng/ml, respectively. Moreover, as CKD stage increased, 
Hb levels decreased with a statistically significant difference between stage 
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3a and stage 1. Serum ferritin levels were higher, while serum levels of 
iron and TIBC were lower, as CKD stage increased, with significant 
differences between stage 2 and stage 1. TSAT also showed decreasing 
trend with the progression of CKD stages. WBC count was higher in CKD 
stage 4 than in stage 1, whereas hsCRP level was higher in stage 2–5 than 
in stage 1. 
Multivariate linear regression analysis of factors associated with serum 
hepcidin levels showed that lower Hb levels and eGFR and higher levels of 
inflammatory markers (hsCRP and WBC counts) and iron markers (TSAT 
and ferritin) were independently associated with higher serum hepcidin levels 
(Table 1.3). These findings were confirmed in multivariate logistic regression 
for high serum hepcidin (Table 1.4). CKD stage was independently 
associated with high serum hepcidin, particularly when comparing CKD 
stage 3b and higher with stage 1. Subgroup analysis by CKD stages (Table 
1.5) showed that lower Hb level and higher CRP, ferritin, and TSAT were 
associated with higher serum hepcidin levels in early and advanced CKD. 
However, decreased eGFR was associated with higher hepcidin in advanced, 
but not in early, CKD. 
In subgroup analysis according to the causes of CKD, eGFR was 
negatively associated with serum hepcidin levels in HN and GN. WBC 
counts were positively associated with serum hepcidin levels, only in DMN, 
whereas hsCRP levels were positively associated with serum hepcidin levels 
in GN and others. ESA use was positively associated with serum hepcidin 
levels, regardless of causes of CKD. Generally, levels of Hb and iron 
indices were associated with serum hepcidin levels, regardless of causes of 
CKD (Table 1.6).
We found that both ESA treatment and iron supplementation were 
associated with higher serum hepcidin levels (Table 1.3). Subgroup analysis 
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by CKD stages showed that serum hepcidin levels were associated with iron 
supplementation in patients with early CKD, and with ESA treatment in 
patients with advanced CKD (Table 1.5). Multivariate logistic regression 
analysis showed that ESA treatment, but not iron supplementation, was 
associated with high serum hepcidin levels (Table 1.4). Assessment of the 
relationships of ESA dose and iron supplement routs with serum hepcidin, 
showed that increased ESA dose was associated with a significant increase 
in the square root of serum hepcidin levels (Figure 1.1). Multivariate logistic 
analysis showed that patients taking 60–120 and ≥120 IU/kg/week ESA 
showed 1.911-fold (P = 0.041) and 2.462-fold (P = 0.049) higher odds for 
high serum hepcidin, respectively, than patients not taking ESA. Although 
the square root of serum hepcidin levels progressively and significantly 
increased from patients not treated with iron supplements to those taking 
oral iron to those taking intravenous iron, multivariate analysis showed that 
iron supplements, regardless of route, were not associated with high serum 
hepcidin (Figure 1.2).
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Table 1.1. Baseline characteristics of the hepcidin quartile group
Serum hepcidin quartile group (n = 2090 ) P-trend
1Q (n = 515) 2Q (n = 529) 3Q (n = 521) 4Q (n = 525)
Age (years) 51.2 ± 12.6 53.8 ± 12.5* 53.8 ± 11.7* 55.4 ±11.7* <0.001
Male sex 49.3 62.0* 66.6* 66.1* <0.001
High income 21.8 25.8 23.5 21.1 0.580
Ever smoking 38.8 45.5* 50.3* 51.6* <0.001
Hypertension 96.3 97.2 97.9 99.0* 0.003
SBP (mm Hg) 125.6 ± 15.4 127.7 ± 15.2 128.5 ± 16.6* 129.3 ± 17.4* <0.001
DBP (mm Hg) 76.7 ± 11.1 77.2 ± 10.3 77.3 ± 11.5 76.8 ± 11.7 0.880
Diabetes 28.2 36.9* 36.5* 43.8* <0.001
Cause of CKD
DMN 17.5 23.6* 26.5* 33.5* < 0.001
  GN 39.0 32.3* 29.4* 24.2* < 0.001
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HN 18.4 22.3 19.4 20.2 0.777
Others 25.0 21.7 24.8 22.1 0.485
BMI (kg/m2) 24.1 ± 3.5 24.6 ± 3.3 25.0 ± 3.5* 24.4 ± 3.3 0.047
Glucose (mmol/l) 5.9 ± 1.9 6.2 ± 2.1 6.3 ± 2.6* 6.2 ± 2.1 0.018
BUN (mmol/l) 8.3 ± 4.8 8.6 ± 4.1 10.1 ± 5.1* 13.3 ± 6.6* <0.001
Creatinine (μmol/l) 128.6 ± 77.6 137.0 ± 72.9 162.4 ± 103.3* 216.9 ± 123.3* <0.001
eGFR (ml/min/1.73m2) 60.8 ± 32.5 55.7 ± 29.6* 48.8 ± 28.5* 36.1 ± 23.9* <0.001
Bilirubin (μmol/l) 11.5 ± 4.7 12.2 ± 5.6 11.6 ± 5.3 10.4 ± 5.0* <0.001
Albumin (g/l) 41.7 ± 3.8 42.2 ± 4.0 41.8 ± 4.3 41.2 ± 4.9 0.013
Cholesterol (mmol/l) 4.6 ± 0.9 4.6 ± 1.0 4.6 ± 1.1 4.4 ± 1.0* 0.002
WBC (×103/μL) 6.4 ± 1.9 6.5 ± 1.8 6.7 ± 1.9 6.8 ± 2.1* 0.001
Hemoglobin (g/dl) 13.0 ± 1.9 13.3 ± 1.8 13.0 ± 2.1 11.9 ± 2.0* <0.001
Anemia 35.9 33.3 42.4* 65.5* <0.001
ESA use 2.9 3.8 5.4* 18.4* <0.001
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SBP, systolic blood pressure; DBP, diastolic blood pressure; CKD, chronic kidney disease; DMN, diabetic 
nephropathy; GN, glomerulonephritis; HN, hypertensive nephropathy; BMI, body mass index; BUN, blood urea 
nitrogen; eGFR, estimated glomerular filtration rate; WBC, white blood cells; ESA, erythropoiesis stimulating agents; 
TSAT, transferrin saturation; hsCRP, high sensitivity C-reactive protein; UPCR, urine protein-to-creatinine ratio. Values 
are expressed as mean ± standard deviation for normally distributed continuous variables, median (interquartile range) 
for non-normally distributed continuous variables, and percentage for categorical variables. * meant P < 0.05 when 
compared to 1Q of serum hepcidin by using Bonferroni post-hoc analysis of one-way ANOVA for normally 
distributed continuous variables, Mann-Whitney U test for non-normally distributed continuous variables, and chi-square 
test for categorical variables.
Iron use 7.4 8.5 13.7* 29.3* <0.001
TSAT (%) 28.1 ± 12.4 31.4 ± 11.1* 33.4 ± 11.7* 33.6 ± 12.4* <0.001
Ferritin (pmol/l) 95.4 (49.3–163.8) 180.7 (120.6–285.9)* 259.1 (170.5–394.3)* 446.7 (282.0–675.2)* <0.001
Hepcidin (ng/ml) 3.9 (2.7–5.3) 9.4 (7.9–11.3)* 18.1 (15.5–21.1)* 38.1 (29.9–56.8)* <0.001
hsCRP (nmol/l) 4.8 (1.9–12.4) 5.4 (1.9–14.3) 6.7 (2.9–17.1)* 7.6 (2.9–21.9)* <0.001
UPCR (g/g) 0.4 (0.1–1.2) 0.4 (0.1–1.2) 0.5 (0.2–1.8)* 0.7 (0.2–2.1)* <0.001
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Table 1.2. Trends of hemoglobin, iron metabolism and inflammation by the stage of chronic kidney disease
CKD Stage (n =2090) P-trend
1(n = 248) 2 (n = 383) 3a (n = 376) 3b (n = 454) 4 (n = 491) 5 (n = 138)
eGFR (ml/min/1.73m2) 110.9 ± 20.1 73.2 ± 8.6* 52.2 ± 4.3* 37.3 ± 4.3* 23.2 ± 4.4* 11.8 ± 2.4* <0.001
UPCR (g/g) 0.2 (0.1–0.7) 0.2 (0.1–0.7) 0.4 (0.1–1.1)* 0.5 (0.2–1.6)* 1.0 (0.3–2.6)* 1.5 (0.7–3.9)* <0.001
Hemoglobin (g/dl) 14.0 ± 1.5 14.1 ± 1.7 13.5 ± 1.9* 12.7 ± 1.8* 11.5 ± 1.5* 10.5 ± 1.2* <0.001
TSAT (%) 34.3 ± 14.7 32.8 ± 12.5 32.4 ± 11.6 30.8 ± 10.8* 29.9 ± 11.5* 30.6 ± 12.0 <0.001
Serum iron (μmol/l) 19.2 ± 7.5 18.0 ± 6.6* 17.6 ± 6.3* 16.0 ± 5.6* 19.2 ± 7.5* 18.0 ± 6.6* <0.001
Serum TIBC (μmol/l) 57.4 ± 8.7 55.9 ± 8.4* 54.8 ± 8.6* 52.9 ± 9.0* 57.4 ± 8.7* 55.9 ± 8.4* <0.001
Ferritin (pmol/l) 170.3 (75.0–349.1) 223.5 (111.6–406.1)* 232.3 (129.2–380.8)* 204.7 (118.1–400.2)* 243.9 (136.0–404.4)* 278.6 (139.1–472.4)* <0.001
Hepcidin (ng/ml) 7.7 (3.8–14) 11.5 (5.7–18.6)* 11.6 (6.4–20.3)* 12.5 (6.9–25.2)* 20.5 (9.9–35.3)* 31.6 (15.6–60.2)* <0.001
WBC (×103/μl) 6.3 ± 1.8 6.5 ± 2.0 6.5 ± 1.9 6.7 ± 1.9 7.0 ± 2.0* 6.3 ± 1.8 0.001
hsCRP (nmol/l)
3.8 (1.0–10.1) 5.7 (1.9–15.2)* 5.7 (1.9–12.6)* 5.7 (2.9–17.9)* 7.6 (3.3–21.0)* 5.7 (2.4–16.2)* <0.001
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CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; UPCR, urine protein-to-creatinine ratio; 
TSAT, transferrin saturation; WBC, white blood cells; hsCRP, high sensitivity C-reactive protein. Values are expressed 
as mean ± standard deviation for normally distributed continuous variables and median (interquartile range) for 
non-normally distributed continuous variables. P-trend was analyzed by a linear-term of one-way ANOVA for 
normally distributed variables and Jonckheere-Terpstra test for non-normally distributed variables. * meant P < 0.05 
when compared to CKD stage 1 by using Bonferroni post-hoc analysis of one-way ANOVA for normally distributed 
variables and Mann-Whitney U test for non-normally distributed variables. 
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Table 1.3. Linear regression analysis for the square root of serum hepcidin 
level.
Univariate Multivariate
Beta (95% CI) P Beta (95% CI) P
Age (years) 0.019 (0.012–0.025) <0.001 -0.003 (-0.008–0.002) 0.310
Sex (men vs. female) 0.348 (0.183–0.513) <0.001 -0.125 (-0.300–0.050) 0.160
Income (high vs. non-high) -0.114 (-0.308–0.081) 0.252 - -
Ever smoking (yes vs. no) 0.267 (0.106–0.429) 0.001 0.060 (-0.094–0.213) 0.447
SBP (mm Hg) 0.011 (0.006–0.016) <0.001 0.002 (-0.001–0.006) 0.243
DBP (mm Hg) -0.002 (-0.010–0.005) 0.536 - -
BMI (kg/m2) 0.014 (-0.009–0.038) 0.236 - -
Glucose (mmol/l) 0.038 (0.001–0.075) 0.042 -0.015 (-0.042–0.012) 0.284
eGFR (ml/min/1.73m2) -0.021 (-0.023– -0.018) <0.001 -0.007 (-0.009–-0.004) <0.001
Albumin (g/l) -0.031 (-0.050– -0.012) 0.001 0.032 (0.015–0.049) <0.001
Cholesterol (mmol/l) -0.184 (-0.263– -0.105) <0.001 -0.036 (-0.096–0.024) 0.239
WBC (×103/μl) 0.056 (0.014–0.098) 0.008 0.044 (0.012–0.077) 0.007
hsCRP (nmol/l) 0.229 (0.170–0.288) <0.001 0.095 (0.051–0.139) <0.001
UPCR (g/g) 0.160 (0.108–0.211) <0.001 0.012 (-0.035–0.06) 0.607
Hemoglobin (g/dl) -0.234 (-0.272– -0.195) <0.001 -0.222 (-0.264–-0.181) <0.001
Ferritin (pmol/l) 1.310 (1.243–1.377) <0.001 1.226 (1.157–1.295) <0.001
TSAT (%) 0.027 (0.020–0.034) <0.001 0.011 (0.006–0.017) <0.001
ESA use (yes vs. no) 1.951 (1.659–2.244) <0.001 0.802 (0.563–1.041) <0.001
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SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body 
mass index; eGFR, estimated glomerular filtration rate; WBC, white blood 
cells; hsCRP, high sensitivity C-reactive protein; UPCR, urine 
protein-to-creatinine ratio; TSAT, transferrin saturation; ESA, erythropoiesis 
stimulating agents. Logarithmic transformations were done for hsCRP, UPCR 
and ferritin. In multivariate linear regression analysis, variables with P < 
0.05 in univariate linear regression analysis were chosen as covariates.  
Iron use (yes vs. no) 1.545 (1.327–1.763) <0.001 0.306 (0.120–0.492) 0.001
Bilirubin   (μmol/l) -0.045 (-0.061– -0.030) <0.001 0.012 (-0.002–0.026) 0.082
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Table 1.4. Logistic regression analysis for the high serum hepcidin
Univariate Multivariate
OR (95% CI) P OR (95% CI) P
Age (year) 1.017 (1.009–1.026) <0.001 1.004 (0.992–1.016) 0.541
Sex (men vs. women) 1.335 (1.085–1.641) 0.006 1.122 (0.742–1.697) 0.585
Income (high vs. non-high) 0.859 (0.674–1.095) 0.220 - -
Ever smoking (yes vs. no) 1.310 (1.075–1.597) 0.008 1.119 (0.782–1.600) 0.540
Hypertension (yes vs. no) 3.079 (1.216–7.798) 0.018 1.205 (0.356–4.078) 0.764
Diabetes (yes vs. no) 1.521 (1.243–1.861) <0.001 0.854 (0.622–1.174) 0.332
BMI (kg/m2) 0.989 (0.960–1.019) 0.462 - -
CKD stages (vs. stage 1) <0.001 <0.001
Stage 2 1.759 (1.044–2.964) 0.034 1.621 (0.869–3.024) 0.129
Stage 3a 1.951 (1.163–3.273) 0.011 1.250 (0.650–2.404) 0.504
Stage 3b 3.444 (2.118–5.602) <0.001 2.293 (1.208–4.354) 0.011
Stage 4 6.429 (4.002–10.327) <0.001 3.639 (1.881–7.038) <0.001
Stage 5 15.980 (9.170–27.847) <0.001 6.958 (3.163–15.305) <0.001
Hemoglobin (g/dl) 0.732 (0.694–0.773) <0.001 0.743 (0.670–0.824) <0.001
TSAT (%) 1.017 (1.009–1.025) <0.001 1.013 (1.000–1.027) 0.044
Ferritin (pmol/l) 1.005 (1.004–1.006) <0.001 1.005 (1.005–1.006) <0.001
ESA use (yes vs. no) 5.375 (3.843–7.517) <0.001 2.031 (1.248–3.305) 0.004
Iron use (yes vs. no) 3.786 (2.944–4.867) <0.001 1.142 (0.767–1.701) 0.512
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OR, odds ratio; CI, confidence interval; BMI, body mass index; CKD, 
chronic kidney disease; TSAT, transferrin saturation; ESA, erythropoiesis 
stimulating agents; WBC, white blood cells; hsCRP, high sensitivity 
C-reactive protein; UPCR, urine protein-to-creatinine ratio. In multivariate 
logistic regression analysis, variables with P < 0.05 in univariate logistic 
regression were chosen as covariates.
WBC (1000/μL) 1.061 (1.008–1.116) 0.022 1.088 (1.010–1.171) 0.026
hsCRP (nmol/l) 1.005 (1.003–1.007) <0.001 1.003 (1.001–1.006) 0.014
UPCR (g/g) 1.111 (1.064–1.159) <0.001 1.010 (0.929–1.098) 0.816
Albumin (g/l) 0.961 (0.940–0.982) <0.001 1.041 (0.996–1.089) 0.074
Cholesterol (mmol/l) 0.797 (0.719–0.884) <0.001 0.948 (0.820–1.096) 0.472
Bilirubin (μmol/l) 0.941 (0.921–0.963) <0.001 1.034 (1.001–1.068) 0.043
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Table 1.5. Subgroup analysis for square root of serum hepcidin level 
according to CKD stages in multivariate linear regression analysis
CKD stage 1-3a CKD stage 3b-5
Beta (95% CI) P Beta (95% CI) P
Age (years) 0.002 (-0.004–0.009) 0.477 -0.003 (-0.011–0.004) 0.397
Sex (men vs. female) 0.105 (-0.124–0.335) 0.369 -0.260 (-0.519–0.000) 0.050
Ever smoking (yes vs. no) 0.075 (-0.113–0.263) 0.433 0.038 (-0.202–0.277) 0.758
SBP (mm Hg) -0.002 (-0.007–0.003) 0.460 0.002 (-0.003–0.007) 0.381
Glucose (mmol/l) -0.010 (-0.051–0.031) 0.641 -0.013 (-0.049–0.023) 0.466
eGFR (ml/min/1.73m2) -0.002 (-0.005–0.001) 0.279 -0.025 (-0.035–-0.015) <0.001
Albumin (g/l) 0.049 (0.026–0.072) <0.001 0.025 (0.001–0.050) 0.045
Cholesterol (mmol/l) 0.023 (-0.056–0.103) 0.569 -0.075 (-0.160–0.010) 0.085
WBC (×103/μl) 0.033 (-0.009–0.076) 0.125 0.049 (0.003–0.096) 0.037
hsCRP (nmol/l) 0.079 (0.021–0.136) 0.008 0.119 (0.055–0.182) <0.001
UPCR (g/g) -0.009 (-0.066–0.047) 0.745 0.019 (-0.059–0.097) 0.632
Hemoglobin (g/dl) -0.165 (-0.221–-0.109) <0.001 -0.187 (-0.250–-0.124) <0.001
Ferritin (pmol/l) 0.939 (0.847–1.031) <0.001 1.460 (1.359–1.562) <0.001
TSAT (%) 0.010 (0.004–0.017) 0.002 0.010 (0.002–0.019) 0.015
ESA use (yes vs. no) -1.366 (-2.944–0.213) 0.090 0.655 (0.386–0.924) <0.001
Iron use (yes vs. no) 0.647 (0.317–0.978) <0.001 0.125 (-0.104–0.354) 0.284
Bilirubin   (μmol/l) 0.013 (-0.002–0.028) 0.093 0.017 (-0.008–0.043) 0.178
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SBP, systolic blood pressure; eGFR, estimated glomerular filtration rate; 
WBC, white blood cells; hsCRP, high sensitivity C-reactive protein; UPCR, 
urine protein-to-creatinine ratio; TSAT, transferrin saturation; ESA, 
erythropoiesis stimulating agents. Logarithmic transformations were done for 
CRP, UPCR and ferritin. Variables with P < 0.05 in univariate linear 
regression analysis were chosen as covariates in multivariate linear regression 
analysis.  
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Table 1.6. Subgroup analysis for square root of serum hepcidin level according to causes of CKD in multivariate 
linear regression analysis
DMN (n = 529) HN (n = 420) GN (n = 652) Others (n = 488)
Adj. Beta   (95% CI) P Adj. Beta   (95% CI) P Adj. Beta   (95% CI) P Adj. Beta   (95% CI) P
eGFR (ml/min/1.73m2) -0.007 (-0.014–0.001) 0.083 -0.016 (-0.023–-0.008) <0.001 -0.006 (-0.010–-0.002) 0.005 -0.004 (-0.009–0.002) 0.178
UPCR (g/g) 0.096 (-0.038–0.230) 0.161 0.034 (-0.074–0.142) 0.534 0.046 (-0.055–0.146) 0.372 -0.062 (-0.180–0.057) 0.306
WBC (×103/μl) 0.105 (0.035–0.175) 0.003 0.050 (-0.033–0.133) 0.240 0.013 (-0.044–0.069) 0.657 0.052 (-0.027–0.131) 0.196
hsCRP (nmol/l) 0.049 (-0.055–0.153) 0.358 0.033 (-0.075–0.142) 0.548 0.193 (0.110–0.276) <0.001 0.115 (0.024–0.205) 0.013
Hemoglobin (g/dl) -0.290 (-0.388–-0.192) <0.001 -0.120 (-0.216–-0.025) 0.014 -0.207 (-0.285–-0.129) <0.001 -0.256 (-0.355–-0.157) <0.001
Ferritin (pmol/l) 1.276 (1.112–1.440) <0.001 1.339 (1.165–1.514) <0.001 1.118 (0.992–1.244) <0.001 1.191 (1.049–1.332) <0.001
TSAT (%) 0.019 (0.004–0.034) 0.012 0.008 (-0.005–0.02) 0.247 0.010 (0.002–0.019) 0.021 0.009 (-0.002–0.02) 0.118
ESA use (Yes vs. no) 0.435 (0.003–0.867) 0.049 1.155 (0.466–1.844) 0.001 0.602 (0.141–1.062) 0.011 1.090 (0.488–1.692) <0.001
Iron use (Yes vs. no) -0.017 (-0.381–0.346) 0.926 0.528 (0.015–1.041) 0.044 0.547 (0.165–0.930) 0.005 0.497 (0.109–0.884) 0.012
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CKD, chronic kidney disease; DMN, diabetic nephropathy; HN, hypertensive nephropathy; GN, glomerulonephritis; Adj., adjusted; 
eGFR, estimated glomerular filtration rate; UPCR, urine protein-to-creatinine ratio; WBC, white blood cells; hsCRP, high 
sensitivity C-reactive protein; TSAT, transferrin saturation; ESA, erythropoiesis stimulating agents. Logarithmic transformations 
were done for CRP, UPCR and ferritin. Variables with P < 0.05 in univariate linear regression analysis (all above with age, sex, 
smoking status, systolic blood pressure, fasting glucose, albumin, cholesterol, and bilirubin) were chosen as covariates in 
multivariate linear regression analysis.  
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Figure 1.1. Dose relationship between erythropoietin stimulating agents 
(ESA) usage and serum hepcidin level. S.E., standard error; EPO-E, 
epoetin-equivalent. * meant P < 0.05 when compared to ESA non-use 
group. 
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Figure 1.2. Dose relationship between route of iron supplements and serum 
hepcidin level. S.E., standard error; IV, intravenous. * meant P < 0.05 when 
compared to non-use group. 
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2. Relative contribution of conventional iron indices and 
hepcidin on anemia 
Of the 2238 patients, 561 were excluded: these included 198 with missing 
data on serum hepcidin, Hb, TSAT, ferritin, and usage of ESA or iron, and 
363 patients who have used ESA or iron. Therefore, 1677 patients were 
included in this analysis. The mean age of the 1677 patients was 53.5 years 
and 65.4% were men. The mean eGFR was 54.8 ml/min/1.73 m2 with a 
median UPCR of 0.4g/g creatinine. The mean Hb level was 13.2g/dl with a 
mean TSAT of 31.9%. The median serum levels of hepcidin and ferritin 
were 11.8 ng/ml and 207.2 pmol/l, respectively. The prevalence of mild, 
moderate, and severe anemia was 45.1%, 18.8%, and 4.2%, respectively.
We explored the association between serum hepcidin and iron indices, and 
anemia severity (Table 2.1). Regardless of anemia severity, serum hepcidin 
and iron indices were significantly associated with anemia in univariate 
logistic regression analysis. In multivariate logistic regression analysis, 
however, TSAT and serum hepcidin maintained statistical significance 
whereas serum ferritin lost statistical significance.
We performed a subgroup analysis according to kidney function to 
evaluate the association between serum hepcidin and iron indices, and 
anemia severity (Table 2.2). In patients with early CKD, serum hepcidin 
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was not associated with anemia, regardless of anemia severity. Among iron 
indices, only TSAT was significantly associated with anemia, particularly in 
less severe anemia (Hb <13.0 g/dl and Hb <11.5 g/dl). However, in patients 
with advanced CKD, serum hepcidin was significantly associated with 
anemia, particularly in severe anemia (Hb <11.5 g/dl and Hb <10.0 g/dl), 
whereas the effect of TSAT and ferritin on anemia severity was minimal.
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Table 2.1. Association of serum hepcidin and iron indices with anemia 
severity
Hb, hemoglobin; TSAT, transferrin saturation; OR, odds ratio; CI, confidence 
interval. OR and its CI were calculated using logistic regression analysis. In 
multivariate analysis, TSAT, ferritin and hepcidin were entered into together 
with age, sex, income status, smoking status, body mass index, fasting 
plasma glucose, systolic blood pressure, estimated glomerular filtration rate, 
bilirubin, albumin, and urine protein-to-creatinine ratio. * per 10 % increase 
in TSAT, per 10 pmol/l increase in ferritin, and per 10 ng/ml increase in 
hepcidin.
Outcomes Factors* Univariate Multivariate
Hb OR (95% CI) P OR (95% CI) P
<13 g/dl TSAT (10 %) 0.660 (0.602–0.723) <0.001 0.701 (0.610–0.807) <0.001
Ferritin (10 pmol/l) 0.995 (0.991–0.999) 0.016 1.001 (0.993–1.008) 0.890
Hepcidin (10 ng/ml) 1.175 (1.100–1.255) <0.001 1.200 (1.054–1.367) 0.006
<11.5 g/dl TSAT (10 %) 0.671 (0.595–0.756) <0.001 0.747 (0.620–0.901) 0.002
Ferritin (10 pmol/l) 1.001 (0.996–1.005) 0.785 0.992 (0.984–1.001) 0.072
Hepcidin (10 ng/ml) 1.316 (1.224–1.413) <0.001 1.403 (1.221–1.613) <0.001
<10 g/dl TSAT (10 %) 0.765 (0.612–0.956) 0.019 0.691 (0.484–0.986) 0.041
Ferritin (10 pmol/l) 1.010 (1.003–1.017) 0.006 0.999 (0.988–1.009) 0.798
Hepcidin (10 ng/ml) 1.425 (1.283–1.583) <0.001 1.422 (1.180–1.713) <0.001
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Table 2.2 Subgroup analysis according to the kidney function for the 
association of serum hepcidin and iron indices with anemia severity 
Hb, hemoglobin; TSAT, transferrin saturation; Adj. OR, adjusted odds ratio; 
CI, confidence interval. Adj. OR and its CI were calculated using 
multivariate logistic regression analysis. TSAT, ferritin and hepcidin were 
entered into together with age, sex, income status, smoking status, body 
mass index, fasting plasma glucose, systolic blood pressure, estimated 
glomerular filtration rate, bilirubin, albumin, and urine protein-to-creatinine 
ratio. * per 10 % increase in TSAT, per 10 pmol/l increase in ferritin, and 
per 10 ng/ml increase in hepcidin.
Outcomes Factors* Estimate glomerular   filtration rate
Hb ≥45 ml/min/1.73m2(n=919) <45 ml/min/1.73m2(n=758)
Adj. OR (95% CI) P Adj.OR (95% CI) P
<13.0 g/dl TSAT (10 %) 0.628 (0.515–0.765) <0.001 0.805 (0.648–0.998) 0.048
Ferritin (10 pmol/l) 0.997 (0.984–1.011) 0.677 1.008 (0.997–1.019) 0.179
Hepcidin (10 ng/ml) 1.112 (0.887–1.394) 0.357 1.138 (0.946–1.369) 0.172
<11.5 g/dl TSAT (10 %) 0.672 (0.476–0.950) 0.024 0.791 (0.626–1.001) 0.051
Ferritin (10 pmol/l) 1.006 (0.983–1.030) 0.592 0.993 (0.984–1.003) 0.166
Hepcidin (10 ng/ml) 1.060 (0.684–1.642) 0.794 1.379 (1.173–1.620) <0.001
<10.0 g/dl TSAT (10 %) 0.350 (0.116–1.058) 0.063 0.717 (0.477–1.078) 0.110
Ferritin (10 pmol/l) 1.022 (0.970–1.077) 0.417 1.002 (0.991–1.014) 0.726
Hepcidin (10 ng/ml) 1.293 (0.377–4.436) 0.683 1.360 (1.115–1.659) 0.002
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3. Serum hepcidin and progression of CKD 
Of the 2238 patients, 328 were excluded: these included 198 with missing 
data on serum hepcidin, Hb, transferrin saturation, ferritin, and usage of 
ESA or iron, and 130 patients who missed the follow-up of renal events. 
Therefore, 1910 patients were included in the final analysis. The mean age 
of the 1910 patients was 54.2 years and 61.0% were men. The causes of 
CKD were DMN in 25.6% of patients, HN in 20.1%, GN in 31.1%, and 
other causes in 23.2%. At enrollment, the median serum hepcidin levels 
were 13.4 ng/ml. During a mean of 2.4 years, 333 patients developed renal 
events (17.4%); 165 (8.6%) patients with functional deterioration and 275 
(14.4%) patients with dialysis initiation. 
We analyzed the association between serum hepcidin and renal events 
development. As serum hepcidin levels increased, the hazard of renal events 
development increased in penalized smoothing splines (Figure 3.1). The 
positive association between serum hepcidin and renal events development 
was also identified in Kaplan-Meier`s survival curve analysis (Figure 3.2). 
Compared to the first quartile of serum hepcidin (4.59 years, 95% CI 
4.47-4.70), the estimated mean renal survival was similar in the second 
quartile of serum hepcidin (vs. 4.43 years, 95% CI 4.29-4.57; P = 0.168), 
but shorter in the third (vs. 4.18 years, 95% CI 4.02-4.35; P <0.001) and 
the forth quartile (vs. 3.49 years, 95% CI 3.31-3.67; P <0.001) of serum 
hepcidin. The increased hazard of renal events development with the 
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increase of serum hepcidin was also maintained in multivariate Cox hazard 
regression analysis after adjusting for confounders including kidney function, 
Hb, conventional iron indices and status of ESA or iron usage, and other 
chronic diseases (Table 3.1). 
We performed a subgroup analysis according to the risk factors of renal 
events development using multivariate Cox proportional hazard regression 
analysis (Table 3.2). The hazard of increased serum hepcidin levels was 
evident in diabetic male patients. In addition, the hazard of increased serum 
hepcidin to develop renal events was obvious only in patients with 
decreased kidney function. The hazard of increased serum hepcidin levels 
was also prominent in patients with decreased levels of Hb, TSAT, and 
ferritin. Serum hepcidin levels were independently associated with the renal 
events development only in patients with lower hsCRP levels. 
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Figure 3.1. Penalized smoothing splines showing the relationship between 
serum hepcidin and renal events development. HR, odds ratio; CI, 
confidence interval. The blue line indicated the HR and the black dotted 
line indicated the 95% CI for which serum hepcidin influences the renal 
events development. In multivariate analysis, age, sex, serum ferritin, high 
sensitivity C-reactive protein, transferrin saturation, hemoglobin, usage of 
erythropoiesis stimulating agents or supplemental iron, causes of chronic 
kidney disease, systolic and diastolic blood pressure, fasting plasma glucose, 
smoking status, estimated glomerular filtration rate, bilirubin, albumin, white 
blood cells, and urine protein-to-creatinine ratio were chosen as covariates.
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Figure 3.2. Kaplan-Meier survival curve of serum hepcidin quartile for 
renal events development. *, †, and ‡ meant P < 0.05 when compared to 
the first, second and third quartile of serum hepcidin group, respectively, 
using log-rank test. 
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Table 3.1. Cox-proportional hazard regression analysis of serum hepcidin for 
renal events 
HR, hazard ratio; CI, confidence interval; Q, quartile. HR and its CI were 
analyzed using Cox proportional hazard regression analysis. In multivariate 
analysis, age, sex, serum ferritin, high sensitivity C-reactive protein, and 
variables with P <0.05 in univariate analysis (transferrin saturation, 
hemoglobin, usage of erythropoiesis stimulating agents or supplemental iron, 
causes of chronic kidney disease, systolic and diastolic blood pressure, 
fasting plasma glucose, smoking status, estimated glomerular filtration rate, 
bilirubin, albumin, white blood cells, and urine protein-to-creatinine ratio) 
were chosen as covariates.
Univariate Multivariate
HR (95% CI) P HR (95% CI) P
Serum hepcidin quartile 
  2Q vs. 1Q 1.299 (0.890–1.894) 0.175 1.290 (0.861–1.932) 0.217
  3Q vs. 1Q 1.967 (1.369–2.826) <0.001 1.514 (1.025–2.237) 0.037
  4Q vs. 1Q 3.954 (2.863–5.461) <0.001 1.752 (1.183–2.596) 0.005
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Table 3.2. Subgroup analysis of the association between serum hepcidin and 
renal events development 
Subgroup No. of patients 4Q vs. 1Q of serum hepcidin P
Adjusted HR (95% CI)
Age <55 years   (n =939) 2.025 (1.089–3.763) 0.026
≥55 years (n =971) 1.868 (1.059–3.297) 0.031
Sex Women (n = 745) 1.753 (0.932–3.295) 0.082
Men (n = 1165) 1.865 (1.087–3.200) 0.024
Diabetes No (n = 1390) 1.592 (0.969–2.615) 0.067
Yes (n = 513) 2.102 (1.009–4.378) 0.047
CKD stage Advanced (n = 1001) 1.718 (1.138–2.592) 0.010
Early (n = 909) 4.211 (0.738–24.011) 0.106
Hemoglobin < 12.8 g/dl (n = 952) 1.920 (1.232–2.992) 0.004
≥12.8 g/dl (n = 958) 0.816 (0.249–2.670) 0.736
ESA/iron use No (n = 1567) 1.830 (1.090–3.070) 0.022
Yes (n = 343) 2.068 (1.033–4.141) 0.040
TSAT <30.3% (n = 948) 2.303 (1.309–4.052) 0.004
≥30.3% (n = 962) 1.314 (0.704–2.451) 0.391
Ferritin <223.0 pmol/l(n = 955) 2.451 (1.264–4.750) 0.008
≥223.0 pmol/l(n = 955) 2.863 (0.968–8.467) 0.057
hsCRP <5.71 nmol/l(n = 850) 1.992 (1.086–3.652) 0.026
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HR, hazard ratio; CI, confidence interval; Q, quartile; CKD, chronic kidney 
disease; TSAT, transferrin saturation; ESA, erythropoiesis stimulating agents; 
hsCRP, high sensitivity C-reactive protein. HR and its CI were analyzed 
using Cox proportional hazard regression analysis. In multivariate analysis, 
age, sex, serum ferritin, hsCRP, and variables with P <0.05 in univariate 
analysis (TSAT, hemoglobin, usage of ESA or iron, causes of CKD, systolic 
and diastolic blood pressure, fasting plasma glucose, smoking status, 
estimated glomerular filtration rate, bilirubin, albumin, white blood cells, and 
urine protein-to-creatinine ratio) were chosen as covariates. 
≥5.71 nmol/l(n = 964) 1.643 (0.948–2.848) 0.077
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Discussion
Although several studies have evaluated the clinical significance of serum 
hepcidin in non-dialysis CKD patients, the relationship between kidney 
function and serum hepcidin levels is still inconclusive [17-27]. In this 
analysis, investigator found that serum hepcidin levels inversely correlated 
with kidney function. In multivariate logistic analysis, the association 
between serum hepcidin and kidney function seemed to be non-linear 
because the odds for high serum hepcidin was statistically evident from 
CKD stage 3b, compared to CKD stage 1. Subgroup analysis by CKD stage 
showed that factors associated with anemia (Hb levels), iron metabolism 
(TSAT and ferritin levels) and inflammation (hsCRP levels) were associated 
with serum hepcidin levels, regardless of CKD stages. In contrast, eGFR 
was associated with serum hepcidin levels only in patients with advanced 
(stages 3b–5), but not in early (stage 1–3a) CKD, suggesting that the 
pathogenesis of elevated serum hepcidin may differ in advanced and early 
CKD, and that decreased renal clearance may significantly contribute to 
elevated serum hepcidin levels in advanced CKD. However, the meaning of 
the null-association between kidney function and serum hepcidin levels in 
patients with DMN and others (mostly ADPKD), is not clarified with this 
study, and needs to be studied more in the future. 
Investigator found that studies reporting kidney function as an independent 
predictor of serum hepcidin levels have used cELISA [17, 18, 23-25], 
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whereas studies suggesting kidney function as a confounding factor for 
serum hepcidin levels have used mass spectrometry (MS) [19-22], when 
measuring serum hepcidin levels. Therefore, the lack of agreement between 
studies assessing kidney function as a predictor of serum hepcidin levels 
may be derived from different assay methods. The bioactive isoform of 
serum hepcidin is hepcidin-25. However, hepcidin can exist in other 
isoforms, such as hepcidin-20, 22 and 24 [45]. Although MS can 
differentiate among hepcidin isoforms, cELISA is poor at differentiating 
hepcidin-25 from other isoforms [46, 47]. If the association between 
hepcidin and kidney function is affected by hepcidin isoforms [21], then 
hepcidin measured by cELISA and by MS may possess different clinical 
meanings. 
Hepcidin and ESA resistance
This study also found that treatment with ESA was significantly 
associated with increased serum hepcidin levels, particularly in patients with 
advanced CKD. Moreover, investigator observed a positive relationship 
between serum hepcidin and ESA dose. The positive association between 
ESA use and serum hepcidin levels was not affected by causes of CKD. 
These results differ from those of previous studies. Ashby et al. measured 
serum hepcidin levels in seven CKD patients as they were starting ESA (20 
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mg darbepoietin alfa weekly) for the first time. Plasma hepcidin fell from 
70.0±4.7 to 60.7±6.0 ng/ml during the first few days (P = 0.045) and 
remained at similar levels when patients were retested after 2–4 weeks of 
continued therapy [17]. The findings are confirmed by van der Putten et al. 
who analyzed EPOCARES trial. In this study, the hepcidin level decreased 
after 2 weeks of ESA treatment [28]. 
These previous studies, however, found that ESA affected serum hepcidin 
level, not vice versa. Unlike these studies, investigator identified the positive 
association between ESA dose and hepcidin levels. In this study, ESA users 
showed lower Hb levels despite of higher iron supplement. Also they 
revealed more iron sequestration (higher serum ferritin despite of similar 
TSAT) than ESA non-users. Taken together, we assumed that higher 
hepcidin level has caused the necessity of ESA prescription. To identify the 
effect of hepcidin on ESA responses, therefore, future prospective studies 
should compare the ESA response, such as change of Hb and iron indexes, 
in both high and low serum hepcidin group.
The current study also found that iron supplementation was associated 
with increased serum hepcidin level, in agreement with previous studies [20, 
22]. In addition, investigator observed a positive association between iron 
supplementation and serum hepcidin levels in patients with early, but not 
advanced, CKD. In this cohort patients, serum hepcidin levels are about 
two-fold higher in advanced than in early CKD. This may be the reason 
why iron supplements was not associated with high (≥25.1 ng/ml) serum 
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hepcidin. 
Hepcidin, iron indices, and anemia severity
Serum ferritin levels were not related to anemia and its severity. Although 
the serum ferritin levels in CKD patients were still related to hepatosplenic 
iron stores [48], those in CKD patients did not correlate with bone marrow 
iron stores [33, 48, 49]. This iron sequestration in CKD patients may nullify 
the association between serum ferritin and anemia status. The null-association 
between serum ferritin and anemia status was evident even in patients with 
early CKD. This implied that the iron sequestration in CKD patients may 
occur in the early stage of CKD. Hepcidin induces iron sequestration. Serum 
hepcidin levels in CKD patients are higher than those of healthy volunteer 
[24, 25]. Taken together, investigator can hypothesize that a small elevation 
of serum hepcidin even in early CKD may nullify the effect of serum 
ferritin on Hb levels.       
In the current study, unlike ferritin, TSAT was independently related to 
anemia and its severity, which was in accordance with the fact that TSAT 
is more predictive of bone marrow iron contents [33] and Hb response after 
intravenous iron replacement [50] than ferritin in CKD patients. Serum 
hepcidin was also significantly associated with anemia of several severities 
in non-dialysis CKD patients. In subgroup analysis according to the CKD 
stages, TSAT was associated well with less severe anemia in patients with 
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early CKD, whereas serum hepcidin was significantly related to more severe 
anemia in patients with advanced CKD. These suggest that TSAT is a 
major determinant of anemia in early CKD patients, whereas serum hepcidin 
is a key determinant of anemia in advanced CKD patients. 
Hepcidin and CKD progression
As serum hepcidin levels increased, the hazard of renal events 
development increased steadily as demonstrated in penalized smoothing 
splines analysis. The hazards to develop renal events of the third and the 
forth quartiles of serum hepcidin were 1.51-times and 1.75-times higher than 
that of the first quartile of serum hepcidin, respectively. To our knowledge, 
this was the first study which showed the independent hazard of serum 
hepcidin on future renal events development. Although the exact mechanism 
has not been fully elucidated, investigator postulated that the intimate 
association between serum hepcidin levels, inflammation, cardiovascular risk 
factors and disturbed homeostasis in anemia and iron metabolism [13, 16] 
may explain the harmful impact of increased serum hepcidin on the 
progression of CKD partly. However, the dangerous effect of serum hepcidin 
on the progression of CKD was independent from those confounding factors. 
We assumed that increased oxidative stress, mitochondrial dysfunction, and 
increased arterial stiffness shown in subjects with increased serum hepcidin 
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levels could be a good explanation for the possible underlying mechanisms 
[51, 52].
 In subgroup analysis, diabetic patients are at increased risk of CKD 
progression by increased serum hepcidin levels than non-diabetic patients. 
Men are affected more by increased serum hepcidin levels than women. 
Investigator also identified that patients with disturbed homeostasis in anemia 
and iron metabolisms (lower levels of Hb, TSAT, and ferritin) were 
influenced more by increased serum hepcidin levels. The harmful effect of 
increased serum hepcidin was evident in patients with lower levels of eGFR 
and hsCRP.
Limitations
The study had several limitations. First, as the study was observational, a 
causal relationship cannot be accurately determined and the results need to 
be interpreted carefully. Second, investigator measured serum hepcidin by 
cELISA only, which cannot distinguish among hepcidin isoforms. Since there 
have been no known methods which provide best clinical implication yet, 
additional studies are required to determine more accurate methods of 
measuring hepcidin level and to determine the significance of hepcidin 
isoforms other than hepcidin-25 [53]. Third, investigator did not have data 
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on the causes of anemia because KNOW-CKD was not designed specifically 
for anemia in CKD. Fourth, there were no data from healthy volunteers and 
patients with ESRD on dialysis. Fifth, a mean of 2.4 years was relatively 
short. Therefore, long-term effect of increased serum hepcidin needs to be 
analyzed in the next studies. Finally, although our study included a large 
number of patients, they were from a single nation with a single ethnic 
group, limiting the generalizability of our results. 
Conclusions
Decreased kidney function was associated with increased serum hepcidin 
levels, especially in patients with advanced CKD. Decreased Hb levels and 
higher levels of iron markers were also associated with higher serum 
hepcidin levels. Iron supplementation was positively correlated with serum 
hepcidin levels, especially in patients with early CKD. The higher hepcidin 
level in ESA users, particularly in those with advanced CKD, suggests that 
hepcidin is a key peptide in ESA resistance. Ferritin was not associated 
with anemia, regardless of the severity of anemia and the level of kidney 
function. TSAT was associated with less severe anemia in patients with 
early CKD, while serum hepcidin was associated with more severe anemia 
in patients with advanced CKD. Increased serum hepcidin levels 
independently predict the progression of CKD in non-dialysis CKD patients. 
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Diabetic male patients with anemia and iron deficiency tended to be affected 
more by the increased serum hepcidin levels. The results of this study may 
prompt future longitudinal studies on the clinical significance of serum 
hepcidin, measured by cELISA, in non-dialysis CKD patients. 
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만성콩팥병 환자의 임상 경과에 
혈청 hepcidin이 미치는 영향에 대한 
연구
배경
빈혈은 만성콩팥병 환자들에게 흔하며 심혈관 질환, 입원 및 사망의 위
험도를 높이므로 적절한 지표를 통해 만성콩팥병 환자의 빈혈을 잘 감시
하고 치료하는 것은 매우 중요하다.
혈청 hepcidin은 체내 철 이용을 억제하는 물질로 주로 콩팥에서 배설되
므로 콩팥기능이 감소하면서 증가한다. 만성콩팥병 환자에서 hepcidin 이 
증가하면 저장철이 충분함에도 불구하고 철분 사용이 원활하지 않아 빈
혈이 발생하며, 이런 경우 기존에 사용하던 페리틴은 빈혈에 대한 좋은 
지표가 될 수 없다. 또한 만성콩팥병 환자에서는 콩팥에서 생성되는 조
혈호르몬이 감소되어 빈혈이 생기므로 치료를 위해 조혈호르몬을 투여하
는데, 조혈호르몬 저항성이 있는 경우에는 빈혈이 잘 교정되지 않아 문
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제가 된다. 특히, 당뇨병과 같은 경우 이런 조혈호르몬 저항성이 더욱 
있을 것으로 생각되며, 원인질환에 따라 신장기능 감소에 따른 hepcidin 
증가정도가 다르고, 이로 인한 조혈호르몬 저항성에도 차이가 있을 것으
로 생각된다. 소규모 단일 기관 연구들에서 hepcidin이 페리틴 보다 철분
의 지표로 우월하며 hepcidn 이 조혈호르몬 저항성과 관련이 있다는 보
고를 했으나 아직까지 대규모 다기관 코호트에서 확인된 바는 없다. 또
한, 만성콩팥병 환자에서 hepcidin 이 콩팥병의 진행에 미치는 영향에 대
해서는 아직까지 연구된 바가 없다.
이에 본 연구자는 대규모 다기관 코호트 자료를 이용하여 기존의 
hepcidin의 임상적 특징 및 조혈호르몬 저항성과의 관련성을 확인하고, 
혈청 hepcidin이 만성 콩팥병의 진행에 미치는 영향에 대해 알아보고자 
본 연구를 진행하게 되었다. 
방법
2011년부터 2016년까지 성인 만성콩팥병 1기-투석 전 5기 까지의 환자
들 2238 명의 환자들이 등록된 다기관 전향적 코호트의 기본 자료를 분
석했다. 대상자의 평균나이는 54.2세였다. 2238명중 혈청 hepcidin 값을 
측정한 2113명을 대상으로 연구를 진행했다. 트랜스페린 포화도와 페리
틴을 철 지표로 사용했다. 빈혈은 남성은 혈색소 13.0 g/dl 이하, 여성은 
12.0 g/dl 이하로 정의했고, 경도, 중등도, 중증의 빈혈은 각각 혈색소 
13.0 g/dl 이하, 11.5 g/dl 이하, 10.0 g/dl 이하로 정의하였다. 코호트 환자
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들은 1년마다 중요 임상지표들을 추적관찰 했으며, 만성 콩팥병의 진행
은 신기능의 50% 이상의 감소, 크레아티닌의 2배 상승 혹은 투석의 시
작으로 정의하였다. 
결과
혈청 hepcidin 과의 관계에 있어서 혈액 내 염증수치와 철 지표들은 만
성콩팥병의 병기와 무관하게 양의 상관관계를 보였다. 그러나 사구체여
과율은 콩팥 기능이 저하된 환자들에서만 (만성 콩팥병 3b-5기) 통계적
으로 유의한 음의 상관관계를 보였다. (beta -0.007, P < 0.001) 철분 치
료 여부는 콩팥 기능이 유지된 환자들에서만 (만성 콩팥병 1-3a기) 혈청 
hepcidin 값과 양의 상관관계를 보인 반면 (beta 0.306, P = 0.001), 조혈 
호르몬 사용은 콩팥 기능이 저하된 환자들에서만 (만성 콩팥병 3b-5기) 
독립적인 양의 상관관계를 보였다 (beta 0.802, P < 0.001). 원인 질환별 
분석에서, 콩팥 기능은 고혈압성 신병증 및 사구체 신염 환자에서 통계
적으로 유의한 음의 상관관계를 보였다. 조혈 호르몬의 사용은 원인 질
환과 무관히 혈청 hepcidin값과 양의 상관관계를 보였다.
트랜스페린 포화도와 혈청 hepcidin은 빈혈의 중등도와 상관없이 빈혈과 
관련성이 있었지만, 혈청 페리틴은 빈혈과 관련성이 없었다. 만성 콩팥
병 1-3a기의 환자에서 트랜스페린 포화도의 10%의 상승은 중증 빈혈 
(오즈비 0.628, 95% 신뢰구간 0.515-0.765; P < 0.001)과 중등도 빈혈 (오
즈비 0.672, 95% 신뢰구간 0.476-0.950; P = 0.024)와 관련성이 있었다. 
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그러나, 만성 콩팥병 3b-5기의 환자에서는 10 ng/ml의 혈청 hepcidin의 
상승이 경도 빈혈 (오즈비 1.360, 95% 신뢰구간 1.115-1.659; P=0.002)와 
중등도 빈혈 (오즈비 1.379, 95% 신뢰구간 1.173-1.620; P <0.001)과 관련
성을 보였다.
코호트 환자들의 평균 관찰 기간은 2.4 년이었고, 관찰에서 탈락하지 않
은 1910명 중 333명의 환자에서 만성 콩팥병의 진행이 발생했다 (17.4%). 
신기능의 50% 감소 및 크레아티닌 2배 상승에 해당되는 환자는 165명 
(8.6%) 이었고, 투석을 시작한 환자는 275명 (14.4%) 이었다. 혈청 
hepcidin 값이 증가함에 따라 만성 콩팥병 진행의 위험도는 지속적으로 
증가했고 다변량 콕스 비례위험모형에서 hepcidin 1 사분위수에 비해 3 
사분위수와 4 사분위수의 위험비 (95% 신뢰구간)는 각각 1.514 
(1.025-2.237, P = 0.037)과 1.752 (1.183-2.596, P = 0.005)이었다. 세부 분
석에서 당뇨가 있는 남성이면서 혈색소 값, 트랜스페린 포화도, 페리틴
이 낮고, 콩팥 기능이 저하되어 있고, 염증수치가 낮은 환자들의 경우 
혈청 hepcidin이 높았을 때 만성 콩팥병이 진행할 위험이 더 높았다.
결론
본 연구에서 신기능과 혈청 hepcidn 값이 독립적인 음의 상관관계가 있
음을 대규모 코호트를 통해 확인했다. 혈청 hepcidin 값은 조혈 호르몬을 
높은 용량으로 사용한 환자에서 높았는데, 이는 hepcidin이 조혈 호르몬 
저항성에 기여하고 있음을 시사한다. 본 연구에서 페리틴은 만성 콩팥병 
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환자에서 빈혈과 관련성이 없었지만, 트랜스페린 포화도는 초기 콩팥병 
환자들에 있어서 비교적 경한 빈혈과 관련성을 보였고 혈청 hepcidin은 
진행성 콩팥병 환자들에서 중증의 빈혈과 관련성을 보였다. 혈청 
hepcidin 과 콩팥병 진행에 대한 연구에서는 초기 혈청 hepcidin 값이 높
을수록 향후 만성 콩팥병 진행의 위험이 증가함을 확인했고, 이런 
hepcidin의 위험도는 당뇨가 있는 남성에서 콩팥기능이 저하되어 있고, 
철 결핍과 빈혈이 있으며 염증수치가 낮을 때 분명했다. 헵시딘이 콩팥
병 진행 및 사망률 둥에 미치는 영향에 대해서는 추가적인 추적자료가 
필요할 것으로 생각된다. 
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